Program
tacabrutideg
Also written as “Tacabrutideg”, “BGB-16673” and “[14C]-BGB-16673”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma, B-Cell, Marginal Zone · Chronic Urticaria, led by BeOne Medicines.
Furthest: phase 3, since Feb 21, 20258 company-led studies, 7 open or runningNext primary completion: Nov 30, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 87 open or running | phase 3since Feb 21, 2025 | Aug 9, 2021 | Nov 30, 2026phase 1 · NCT07005713 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 9, 2021First study: phase 2 study in Lymphoma, B-Cell, Marginal ZoneFirst studyNCT05006716 · 689 planned · United States, Australia, Brazil and more
- Feb 22, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05294731 · 146 planned · China
- Jan 10, 2025Phase 1 study in Healthy VolunteersNCT06776679 · 8 enrolled · United States
- Feb 21, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06846671 · 250 planned · United States, Argentina, Australia and more
- May 6, 20252 phase 3 studies in Leukemia, Lymphocytic, Chronic, B-CellNCT06970743, NCT06973187
- May 22, 2025Phase 1 study in Chronic UrticariaNCT07005713 · 58 planned · China
- Sep 29, 2026Phase 1 study in Hepatic ImpairmentNCT07856004 · 24 planned
- Oct 5, 2026Primary completion moved from 2026-11 to 2027-03Date moved laterphase 2 · +4 months · NCT05006716
Ahead
- Nov 30, 2026Primary completion: phase 1 study in Chronic UrticariaNCT07005713
- Mar 2027Primary completion: phase 2 study in Lymphoma, B-Cell, Marginal ZoneNCT05006716
- Jun 30, 2027Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT05294731
- Jul 31, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07856004
TargetBeta
BTK →read by rule
“An orally bioavailable, targeted degrader of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) by using the proteolysis targeting chimera (PROTAC) technology, ”NCIt, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07856004Hepatic Impairment | 1 | Not yet recruiting | Jul 31, 2027 | 24 |
| NCT07005713Chronic Urticaria · China | 1 | Recruiting | Nov 30, 2026 | 58 |
| NCT06973187Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Recruiting | Apr 17, 2028 | 500 |
| NCT06970743Leukemia, Lymphocytic, Chronic, B-Cell · China, Taiwan | 3 | Active, not recruiting | Nov 30, 2029 | 153 |
| NCT06846671Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Recruiting | May 15, 2028 | 250 |
| NCT06776679Healthy Volunteers · United States | 1 | Completed | Mar 27, 2025 | 8 |
| NCT05294731Lymphoma, Non-Hodgkin · China | 2 | Recruiting | Jun 30, 2027 | 146 |
| NCT05006716Lymphoma, B-Cell, Marginal Zone · United States, Australia, Brazil and more | 2 | Recruiting | Mar 2027 | 689 |
How it is read
Names in the registry
- “Tacabrutideg”, 6 entries
- “BGB-16673”, 1 entry
- “[14C]-BGB-16673”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 3 studies
- Lymphoma, Non-Hodgkin, 1 study
- Lymphoma, B-Cell, Marginal Zone, 1 study
- Chronic Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.